Pharmacokinetic Parameters of Protease Inhibitors and the Cmin/IC50 Ratio: Call for Consensus
- 1 June 2001
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 27 (2) , 210-211
- https://doi.org/10.1097/00126334-200106010-00018
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Once-daily indinavir plus ritonavir: preliminary results of the PIPO studyAIDS, 2000
- Dual Protease Inhibitor Therapy in HIV-Infected Patients: Pharmacologic Rationale and Clinical BenefitsAnnual Review of Pharmacology and Toxicology, 2000
- Induction of human herpesvirus-8 gene expression by recombinant interferon gammaAIDS, 2000
- Antiviral Effect and Pharmacokinetic Interaction between Nevirapine and Indinavir in Persons Infected with Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 1999
- Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency VirusVirology, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998